EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Regulatory, Ethical, and Safety Considerations of Exosome‐Based Therapies in Dermatology

Sawyeh Maher, Michael H. Gold

Dermatological Reviews · 2026-04 · 7 (2)

DOI: 10.1002/der2.70071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatological Reviews, online erschienen am 08.04.2026. Verfasst von Sawyeh Maher und 1 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Exosome and stem cell–derived products have rapidly gained popularity in dermatology, particularly in elective settings. Despite their expanding clinical and commercial use, exosome‐based therapies have yet to receive regulatory approval for dermatologic indications, and long‐term safety data remains limited.

Objective

To review the biological background, global regulatory frameworks, safety considerations, and ethical challenges associated with exosome‐based therapies in dermatology, with an emphasis on clinical decision‐making in elective settings.

Methods

A narrative review of current regulatory guidance, published clinical and preclinical literature, and ethical frameworks relevant to exosome and stem cell–derived products was conducted.

Results

Exosome‐based therapies do demonstrate potential regenerative applications in areas such as skin rejuvenation, wound healing, and hair restoration. However, substantial variability in cell sourcing, manufacturing processes, and product characterization makes standardization and regulation complicated. No exosome‐based products have received U.S. Food and Drug Administration (FDA) approval for dermatologic use. Reported adverse reactions, limited longitudinal follow‐up, and variability in international regulatory oversight highlight persistent translational and safety gaps.

Conclusion

While exosome‐based therapies represent an evolving frontier in dermatology, their integration into clinical practice should proceed with caution. Regulatory literacy, transparent informed consent, structured product evaluation, and evidence‐based clinical restraint are essential to ensure patient safety.

Zitieren

APA

Maher, S., & Gold, M. H. (2026). Regulatory, Ethical, and Safety Considerations of Exosome‐Based Therapies in Dermatology. Dermatological Reviews, 7(2). https://doi.org/10.1002/der2.70071

Vancouver

Maher S, Gold MH. Regulatory, Ethical, and Safety Considerations of Exosome‐Based Therapies in Dermatology. Dermatological Reviews. 2026;7(2). doi:10.1002/der2.70071

BibTeX
@article{Maher2026,
  author = {Maher, Sawyeh and Gold, Michael H.},
  title = {Regulatory, Ethical, and Safety Considerations of Exosome‐Based Therapies in Dermatology},
  journal = {Dermatological Reviews},
  year = {2026},
  volume = {7},
  number = {2},
  doi = {10.1002/der2.70071}
}
Kostenlos starten →